TBPH

SEC source: 0001415889-22-011671 · form4-11222022_091120.xml · nonDerivative · entry 2

Hindman Andrew A. · CIK 0001607965 · SVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 384,714

F3 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-22-011669 · form4-11222022_091137.xml · nonDerivative · entry 1

GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 315,604

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-22-011671 · form4-11222022_091120.xml · nonDerivative · entry 1

Hindman Andrew A. · CIK 0001607965 · SVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 409,771

F1 · price: This transaction was executed in multiple trades at prices from $10.7891 to $11.2750. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

F2 · balance_after: Includes 1,264 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 15, 2022.

SEC source: 0001415889-22-011523 · form4-11182022_121128.xml · nonDerivative · entry 1

GRAHAM RICHARD A · CIK 0001820036 · SVP, RESEARCH & DEVELOPMENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 342,954

SEC source: 0001387131-22-009897 · tbph-form4_091622.xml · derivative · entry 2

GSK PLC · CIK 0001131399 · Former 10% Owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Ordinary Shares · 9,256,882 shares

Expires not disclosed

F1 · kind: On September 16, 2022, the previously announced offer by GSK Finance (No.3) plc ("GSK Finance"), a wholly owned indirect subsidiary of GSK plc ("GSK"), to repurchase any and all of its Exchangeable Senior Notes due 2023 (the "Notes") exchangeable into ordinary shares ("Ordinary Shares") of Theravance Biopharma, Inc. ("Theravance Biopharma") expired, and on September 20, 2022, GSK Finance repurchased $269,061,000 aggregate principal amount of the Notes pursuant to that offer. The 9,644,792 Ordinary Shares that underlay the previously outstanding $280,336,000 aggregate principal amount of Notes were held directly by GSK Finance. Following the repurchase of the Notes and the subsequent cancellation of such Notes, $11,275,000 aggregate principal amount of Notes remain outstanding.

F1 · price: On September 16, 2022, the previously announced offer by GSK Finance (No.3) plc ("GSK Finance"), a wholly owned indirect subsidiary of GSK plc ("GSK"), to repurchase any and all of its Exchangeable Senior Notes due 2023 (the "Notes") exchangeable into ordinary shares ("Ordinary Shares") of Theravance Biopharma, Inc. ("Theravance Biopharma") expired, and on September 20, 2022, GSK Finance repurchased $269,061,000 aggregate principal amount of the Notes pursuant to that offer. The 9,644,792 Ordinary Shares that underlay the previously outstanding $280,336,000 aggregate principal amount of Notes were held directly by GSK Finance. Following the repurchase of the Notes and the subsequent cancellation of such Notes, $11,275,000 aggregate principal amount of Notes remain outstanding.

F1 · derivative.exercise_date: On September 16, 2022, the previously announced offer by GSK Finance (No.3) plc ("GSK Finance"), a wholly owned indirect subsidiary of GSK plc ("GSK"), to repurchase any and all of its Exchangeable Senior Notes due 2023 (the "Notes") exchangeable into ordinary shares ("Ordinary Shares") of Theravance Biopharma, Inc. ("Theravance Biopharma") expired, and on September 20, 2022, GSK Finance repurchased $269,061,000 aggregate principal amount of the Notes pursuant to that offer. The 9,644,792 Ordinary Shares that underlay the previously outstanding $280,336,000 aggregate principal amount of Notes were held directly by GSK Finance. Following the repurchase of the Notes and the subsequent cancellation of such Notes, $11,275,000 aggregate principal amount of Notes remain outstanding.

F1 · derivative.expiration_date: On September 16, 2022, the previously announced offer by GSK Finance (No.3) plc ("GSK Finance"), a wholly owned indirect subsidiary of GSK plc ("GSK"), to repurchase any and all of its Exchangeable Senior Notes due 2023 (the "Notes") exchangeable into ordinary shares ("Ordinary Shares") of Theravance Biopharma, Inc. ("Theravance Biopharma") expired, and on September 20, 2022, GSK Finance repurchased $269,061,000 aggregate principal amount of the Notes pursuant to that offer. The 9,644,792 Ordinary Shares that underlay the previously outstanding $280,336,000 aggregate principal amount of Notes were held directly by GSK Finance. Following the repurchase of the Notes and the subsequent cancellation of such Notes, $11,275,000 aggregate principal amount of Notes remain outstanding.

F1 · ownership.nature: On September 16, 2022, the previously announced offer by GSK Finance (No.3) plc ("GSK Finance"), a wholly owned indirect subsidiary of GSK plc ("GSK"), to repurchase any and all of its Exchangeable Senior Notes due 2023 (the "Notes") exchangeable into ordinary shares ("Ordinary Shares") of Theravance Biopharma, Inc. ("Theravance Biopharma") expired, and on September 20, 2022, GSK Finance repurchased $269,061,000 aggregate principal amount of the Notes pursuant to that offer. The 9,644,792 Ordinary Shares that underlay the previously outstanding $280,336,000 aggregate principal amount of Notes were held directly by GSK Finance. Following the repurchase of the Notes and the subsequent cancellation of such Notes, $11,275,000 aggregate principal amount of Notes remain outstanding.

SEC source: 0001387131-22-009897 · tbph-form4_091622.xml · nonDerivative · entry 1

GSK PLC · CIK 0001131399 · Former 10% Owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Corporation

Disclosed balance after: 0

F1 · kind: On September 16, 2022, the previously announced offer by GSK Finance (No.3) plc ("GSK Finance"), a wholly owned indirect subsidiary of GSK plc ("GSK"), to repurchase any and all of its Exchangeable Senior Notes due 2023 (the "Notes") exchangeable into ordinary shares ("Ordinary Shares") of Theravance Biopharma, Inc. ("Theravance Biopharma") expired, and on September 20, 2022, GSK Finance repurchased $269,061,000 aggregate principal amount of the Notes pursuant to that offer. The 9,644,792 Ordinary Shares that underlay the previously outstanding $280,336,000 aggregate principal amount of Notes were held directly by GSK Finance. Following the repurchase of the Notes and the subsequent cancellation of such Notes, $11,275,000 aggregate principal amount of Notes remain outstanding.

F2 · kind: All 9,644,807 Ordinary Shares previously held by GSK were sold back to Theravance Biopharma pursuant to a Stock Repurchase Agreement dated September 16, 2022.

F1 · ownership.nature: On September 16, 2022, the previously announced offer by GSK Finance (No.3) plc ("GSK Finance"), a wholly owned indirect subsidiary of GSK plc ("GSK"), to repurchase any and all of its Exchangeable Senior Notes due 2023 (the "Notes") exchangeable into ordinary shares ("Ordinary Shares") of Theravance Biopharma, Inc. ("Theravance Biopharma") expired, and on September 20, 2022, GSK Finance repurchased $269,061,000 aggregate principal amount of the Notes pursuant to that offer. The 9,644,792 Ordinary Shares that underlay the previously outstanding $280,336,000 aggregate principal amount of Notes were held directly by GSK Finance. Following the repurchase of the Notes and the subsequent cancellation of such Notes, $11,275,000 aggregate principal amount of Notes remain outstanding.

SEC source: 0001415889-22-008979 · form4-08232022_030819.xml · nonDerivative · entry 1

Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 319,577

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-22-008985 · form4-08232022_040838.xml · nonDerivative · entry 1

Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,424,784

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-22-008983 · form4-08232022_040813.xml · nonDerivative · entry 1

Hindman Andrew A. · CIK 0001607965 · SVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 473,507

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-22-008981 · form4-08232022_030844.xml · nonDerivative · entry 1

GRAHAM RICHARD A · CIK 0001820036 · SVP, DEVELOPMENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 345,754

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-22-008835 · form4-08182022_030816.xml · nonDerivative · entry 1

GRAHAM RICHARD A · CIK 0001820036 · SVP, DEVELOPMENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 364,745

F1 · price: This transaction was executed in multiple trades at prices from $9.71 to $9.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-22-008512 · form4-08112022_030815.xml · nonDerivative · entry 1

GRAHAM RICHARD A · CIK 0001820036 · SVP, DEVELOPMENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 369,651

SEC source: 0001415889-22-008006 · form4-07272022_030759.xml · nonDerivative · entry 1

Hindman Andrew A. · CIK 0001607965 · SVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 499,183

F1 · shares: On July 1, 2019, the reporting person was granted a performance stock unit award that vests based on the achievement of certain performance conditions over a three-year timeframe from 2019 through June 30, 2022 and continued employment. On June 30 2022, the performance conditions applicable to 20,000 shares were achieved and such shares will vest on August 20, 2023, subject to the reporting person's continued service.

SEC source: 0001415889-22-005627 · form4-05242022_040525.xml · nonDerivative · entry 2

Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 329,990

F2 · shares: This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 5/17/21.

SEC source: 0001415889-22-005627 · form4-05242022_040525.xml · nonDerivative · entry 1

Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 331,071

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-22-005633 · form4-05242022_040502.xml · nonDerivative · entry 1

Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,440,588

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

F2 · balance_after: Includes 2,313 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 13, 2022.

SEC source: 0001415889-22-005631 · form4-05242022_040517.xml · nonDerivative · entry 1

Hindman Andrew A. · CIK 0001607965 · SVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 479,183

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

F2 · balance_after: Includes 1,263 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 13, 2022.

SEC source: 0001415889-22-005629 · form4-05242022_040517.xml · nonDerivative · entry 1

GRAHAM RICHARD A · CIK 0001820036 · SVP, DEVELOPMENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 384,737

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-22-004328 · form4-04282022_050458.xml · derivative · entry 2

BROSHY ERAN · CIK 0001256230 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Ordinary Shares · 28,000 shares

Expires 2032-04-25

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

SEC source: 0001415889-22-004328 · form4-04282022_050458.xml · nonDerivative · entry 1

BROSHY ERAN · CIK 0001256230 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,886

SEC source: 0001415889-22-004336 · form4-04282022_060457.xml · derivative · entry 2

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Ordinary Shares · 28,000 shares

Expires 2032-04-25

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

SEC source: 0001415889-22-004336 · form4-04282022_060457.xml · nonDerivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,747

SEC source: 0001415889-22-004330 · form4-04282022_050421.xml · derivative · entry 3

MALKIEL BURTON G · CIK 0001184677 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Ordinary Shares · 28,000 shares

Expires 2032-04-25

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

SEC source: 0001415889-22-004330 · form4-04282022_050421.xml · nonDerivative · entry 1

MALKIEL BURTON G · CIK 0001184677 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,457

SEC source: 0001415889-22-004332 · form4-04282022_060430.xml · derivative · entry 2

MITCHELL DEAN J · CIK 0001199297 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Ordinary Shares · 28,000 shares

Expires 2032-04-25

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

SEC source: 0001415889-22-004332 · form4-04282022_060430.xml · nonDerivative · entry 1

MITCHELL DEAN J · CIK 0001199297 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,886

SEC source: 0001415889-22-004339 · form4-04282022_060430.xml · derivative · entry 2

YOUNG WILLIAM D · CIK 0001217420 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Ordinary Shares · 28,000 shares

Expires 2032-04-25

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

SEC source: 0001415889-22-004339 · form4-04282022_060430.xml · nonDerivative · entry 1

YOUNG WILLIAM D · CIK 0001217420 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,010

SEC source: 0001415889-22-004334 · form4-04282022_060449.xml · derivative · entry 2

O'Connor Donal · CIK 0001625377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Ordinary Shares · 28,000 shares

Expires 2032-04-25

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

SEC source: 0001415889-22-004334 · form4-04282022_060449.xml · nonDerivative · entry 1

O'Connor Donal · CIK 0001625377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,886

SEC source: 0001415889-22-004326 · form4-04282022_050440.xml · derivative · entry 2

Smaldone Alsup Laurie · CIK 0001589602 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Ordinary Shares · 28,000 shares

Expires 2032-04-25

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

SEC source: 0001415889-22-004326 · form4-04282022_050440.xml · nonDerivative · entry 1

Smaldone Alsup Laurie · CIK 0001589602 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,662

SEC source: 0001415889-22-002174 · form4-03022022_040301.xml · nonDerivative · entry 1

Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333,271

F1 · shares: This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 5/17/21.

F2 · price: This transaction was executed in multiple trades at prices from $10.02 to $10.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-22-002078 · form4-03012022_040310.xml · derivative · entry 3

Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 515,000

Underlying: Ordinary Shares · 515,000 shares

Expires 2032-02-24

F1 · derivative.exercise_date: 25% of this option may be exercised when the optionee completes 12 months of continuous Service after the Date of Grant. Any remaining unvested shares may be exercised with respect to an additional 1/48th of the shares subject to the option when the optionee completes each month of continuous Service thereafter.

SEC source: 0001415889-22-002078 · form4-03012022_040310.xml · nonDerivative · entry 1

Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,449,300

SEC source: 0001415889-22-001695 · form4-02232022_030255.xml · nonDerivative · entry 1

Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,627

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-22-001701 · form4-02232022_030237.xml · nonDerivative · entry 1

PITZER KENNETH R · CIK 0001668775 · SVP, PROD STRAT & COMM PLNG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 380,123

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-22-001703 · form4-02232022_030205.xml · nonDerivative · entry 1

Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,279,300

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-22-001699 · form4-02232022_030232.xml · nonDerivative · entry 1

Hindman Andrew A. · CIK 0001607965 · SVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 481,285

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-22-001697 · form4-02232022_030221.xml · nonDerivative · entry 1

GRAHAM RICHARD A · CIK 0001820036 · SVP, DEVELOPMENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 388,684

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-22-001693 · form4-02232022_030232.xml · nonDerivative · entry 1

BRADY ANN · CIK 0001767974 · PRESIDENT, TBIL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,319

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-22-001184 · form4-02092022_020249.xml · nonDerivative · entry 1

PITZER KENNETH R · CIK 0001668775 · SVP, PROD STRAT & COMM PLNG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 407,422

SEC source: 0001179110-21-011076 · edgar.xml · nonDerivative · entry 1

Farnum Rhonda · CIK 0001898490 · SVP, Comm & Medical Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 347,451

SEC source: 0001179110-21-010636 · edgar.xml · nonDerivative · entry 1

GRAHAM RICHARD A · CIK 0001820036 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 409,061

SEC source: 0001179110-21-010638 · edgar.xml · nonDerivative · entry 1

Hindman Andrew A. · CIK 0001607965 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 507,258

F1 · shares: On December 2, 2021, the reporting person was granted 340,000 RSUs. 240,000 RSUs are subject to service-based vesting conditions and the remaining 100,000 RSUs vest based on the achievement of share price appreciation targets as well as continued employment.

SEC source: 0001415889-21-005465 · form4-11232021_051137.xml · nonDerivative · entry 1

WORBOYS PHILIP D · CIK 0001668718 · SVP, RESEARCH & TRANSL SCIENCE

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 330,752

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-21-005469 · form4-11232021_051103.xml · nonDerivative · entry 1

PITZER KENNETH R · CIK 0001668775 · SVP, PROD STRAT & COMM PLNG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 355,422

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-21-005463 · form4-11232021_051101.xml · nonDerivative · entry 1

Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,302,010

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-21-005472 · form4-11232021_051113.xml · nonDerivative · entry 1

BRADY ANN · CIK 0001767974 · PRESIDENT, TBIL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,688

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001415889-21-005468 · form4-11232021_051117.xml · nonDerivative · entry 1

GRAHAM RICHARD A · CIK 0001820036 · SVP, DEVELOPMENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

F2 · valueOwnedAfter: Includes 119 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 15, 2021.